Clinical Trials Logo

Leptomeningeal Metastases clinical trials

View clinical trials related to Leptomeningeal Metastases.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06462092 Not yet recruiting - Clinical trials for Leptomeningeal Metastases

Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer

Start date: June 15, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

Leptomeningeal metastases is a specific pattern of central involvement in which tumor cells invade and proliferate in the subarachnoid space, and is a lethal complication of malignant tumors. Leptomeningeal metastases from Her2-negative breast cancer is still tricky to treat at present, with an overall median survival of only 3-6 months, even after aggressive treatment. This study is an open, uncontrolled phase I/II clinical study to observe the safety, feasibility, and potential efficacy of Sacituzumab Govitecan combined with pemetrexed intrathecal chemotherapy in the treatment of patients with Her2-negative breast cancer leptomeningeal metastases in search of a more effective treatment.

NCT ID: NCT03613181 Not yet recruiting - Brain Metastases Clinical Trials

ANG1005 in Leptomeningeal Disease From Breast Cancer

ANGLeD
Start date: December 2023
Phase: Phase 3
Study type: Interventional

This is an open-label Phase 3 study to see if ANG1005 can prolong survival compared to a Physician Best Choice control in HER2-negative breast cancer patients with newly diagnosed leptomeningeal disease and previously treated brain metastases.